|
|
ricerca
nel sito motori di rierca
|
|
|
|
|
documenti nella sezione
|
|
|
analisi della letteratura
in merito alla comunicazione facilitata
(cenciarelli i., mona a., 1999)
autismo:
è legato alla carenza di un enzima? - abstract
(cohen e., 1997)
autismo e linguaggio
(atzori g., 2003)
autismo ed epilessia
(a cura del prof. curatolo p., 1999)
dimetilglicina, un
metabolite non tossico e l'autismo
(rimland b., 1996)
i testi dei facilitati
svolgono le funzioni della lingua parlata?
(cenciarelli i., 1999)
il legame fra il
vaccino mmr e l'autismo ora č pių chiaro
(fracer l., 2000)
il profilo cognitivo
delle persone autistiche
(mona a., 1999)
l'autismo: nuovi
esami per trovarne le cause e migliorarne la prognosi
(hanau c., tratto dal sito 'autismo triveneto', 1999)
l'intervento evolutivo
multicomponenziale (i.e.m.) in soggetti autistici
(guazzo g. m., aliperta d., cozzolino g., fabrizio c., liotta
d., trinchese i., pervenuto alla bma il 12-11-2000)
l'uso di diete senza
glutine e caseina con persone con autismo
(autism research unit, 1999)
la comunicazione
facilitata in ambito giudiziario
(cenciarelli i., mona a., 1999)
le rappresentazioni
della relazione tra operatori e bambini autistici
(d'amore s., onnis l., 1998)
linguaggio segnato
o comunicazione simultanea
(edelson s. m.)
risultati a lungo
termine per bambini con autismo che hanno ricevuto un trattamento
comportamentale intensivo precoce
(O. I. Lovaas, J. J. McEachin, T. Smith, 1993)
ruolo dell'immunogenetica
nella diagnosi di patologie post-vaccinali nel sistema nervoso centrale
- abstract
(montinari m. g., 1995)
secretina, aggiornamento
di dicembre 1999: la questione della sicurezza
(rimland b., 1999)
secretina: notizie
positive e negative alla "fine del primo inning"
(rimland b., 1999)
sistema immunitario
e autismo: alcune considerazioni
(colamaria v., pervenuto alla bma il 18-04-2001)
teoria della mente
e autismo
(atzori g., 2003)
trattamento comportamentale
ed educazione normale e funzionamento intellettivo nei bambini
autistici
(lovaas o. i., 1987)
un trattamento
omeopatico per l'autismo
(micozzi a., benassi f., 2002)
|
|
|
indietro
| inizio
|
|
|
DIMETHYLGLYCINE (DMG), A NONTOXIC METABOLITE, AND AUTISM
B. Rimland, 1996
Autism
Research Institute, 41182 Adams
Avenue, San Diego, CA 92116.
(testo in italiano)
DMG is a rather sweet-tasting substance that was described in a
recent article in the Journal of Laboratory and Clinical Medicine
(1990, 481-86) as a "natural, simple compound with no known
undesirable side effects." The article did not pertain to the
use of DMG in autism, but instead described an experiment in which
DMG was used to try to enhance the function of the immune system
of laboratory rabbits. It worked-the immune systems of the animals
given DMG showed 300% to 1,000% better response to infection than
the controls.
DMG is readily available in many health food stores. It is legally
classified as a food. It does not require a prescription. It is
manufactured by several companies, and comes in various forms, most
commonly in tiny foil-wrapped tablets about 1/3 the size of an aspirin.
The taste is pleasant and children chew the tablets readily. At
about 25 cents per tablet, the cost is minimal, since only one to
eight tablets a day are usually taken (eight for adults).
"So far so good," you may be saying, "but what does
this have to do with autism?"
In 1965, two Russian investigators, M. G. Blumena and T. L. Belyakova,
published a report showing considerable improvement in the speech
of 12 of a group of 15 mentally handicapped children who had not
been able to use speech to communicate. The children had been treated
with a substance variously known as calcium pangamate, or pangamic
acid, or "vitamin B15." In addition to enriched vocabulary,
the children began to use simple sentences, their general mental
state improved, and there was better concentration and interest
in toys and games. Subsequent research has shown the essential factor
in calcium pangamate to be DMG.
Soon afterward psychiatrist Allan Cott visited Moscow and brought
back a small supply of pangamic acid, which he tried on a number
of children in his practice, some of whom were autistic. Many of
Cott's patients responded in the same way the Russian children had.
One mother wrote, "It's the most exciting thing I've ever experienced.
He was repeating words and he answers questions now...."
At about this time pangamic acid, or B15, entered the U.S. market.
Chaos ensued. Every manufacturer touted his product as "the
original Russian formula." There were at least four different
formulas on the market, partly, it is believed, as a result of deliberate
deception and obfuscation on the part of the Russians. DMG, in small
amounts, was a component of some of the formulas. The FDA stepped
in and lengthy legal battles ensued. One outcome is that the term
B15 was outlawed. (Although DMG resembles the B vitamins in many
ways-it is found in the same foods, for example-there are no known
overt symptoms characteristic of a DMG deficiency.)
The significant outcome of the legal battles is that the sale of
DMG is now permitted, as long as it is not referred to as a vitamin,
and as long as it is sold as a food and not a drug.
I have been following the pangamic acid-DMG situation for almost
25 years. I have mentioned it in some of my lectures, and told parents
and professionals about it in conversations and correspondence.
Always I would ask, "if you try it, please let me know what
results you see, even if no improvement is found."
I am now so firmly convinced that DMG is helpful to a substantial
proportion of autistic children and adults that I have decided to
"go public" in the Autism Research Review International
-to tell people about it freely and openly, so they may try it if
they wish.
Some who hear of this boldness may be aghast: "Where are the
double blind placebo-controlled scientific studies showing it to
be effective in autism?" they will ask. My reply is simple.
"There aren't any, and none are needed." There are, of
course, numerous double blind non-autism studies of DMG in the scientific
and medical literature, using not only humans, but many kinds of
laboratory animals, often given very large amounts of DMG. As noted
earlier, no adverse side effects have been found with even massive
intakes of DMG. (I say "intakes" rather than "dosages"
because "dosage" implies that DMG is a drug, which it
is not.)
Since no company has the exclusive right to make DMG, competition
keeps the price-and profits-down. Thus there is almost no chance
that anyone will sponsor a $200,000 double blind study of DMG on
autistic children. A parent can buy 30 tablets for about $8.00.
That is a sufficient supply, even for an adult given five or more
tablets a day, to determine, in most cases, if it will be helpful.
If it is felt to be helpful, fine. If not, you have wasted $8.00
(except for the boost given to the immune system).
To help the parents receive unbiased input, I usually tell them
to refrain from mentioning to teachers, grandparents and others
in the child's environment that DMG is being tried. I have numerous
letters in my files saying, "Johnny's speech therapist says
he has made more progress in the last two weeks than in the last
six months. As you suggested, we had told no one at his school that
we were trying DMG."
I am 100% in favor of double blind studies on drugs with considerable
potential for harm, such as fenfluramine, Haldol, or the like. However,
it doesn't make sense to insist on such refinements before trying
a perfectly safe substance such as DMG, apple pie, or chicken soup.
If DMG is going to work, its effects will usually be seen within
a week or so, though it should be tried for a few weeks or a month
before giving up. In some cases dramatic results have been seen
within 24 hours: A Los Angeles mother was driving on the freeway,
three-year-old Kathy in the back seat, five-year-old mute autistic
son Sammy in the front. DMG had been started the day before. Kathy
began to cry. Sammy turned and spoke his first words: "Don't
cry, Kathy." The mother, stunned, almost crashed the car.
A similar case: A Texas mother secured her six-year-old mute autistic
daughter in the front seat, then, before driving off, turned to
tell her husband, "I'll drop Mary at the babysitter's house
first." Mary, on DMG for two days, startled her parents with
her first words: "No! No babysitter!"
Although speech is the most notable positive change in those children
helped by DMG, behavioral improvement is also often reported. One
father gave his son one DMG tablet per day without mentioning it
to the school. He later requested a copy of the school's detailed
record of his son's day-by-day behavioral transgressions. The correlation
between outburst-free days and the use of DMG was unmistakable.
An article in the New England Journal of Medicine (October
1982) reported that a 22-year-old mentally retarded man who had
16 to 18 seizures per week on standard anticonvulsants, experienced
only three seizures per week while on DMG. Two attempts to remove
the DMG dramatically increased seizure frequency.
Last year I sent information on DMG to Lee Dae Kun, Director of
the Pusan (Korea) Research Center on Child Problems. He tried the
DMG on 39 autistic children, ages three to seven, for three months,
with the following (summarized) results:
Benefits seen
Yes: 31 (80%)
No: 8 (20%)
(Improved speech, eating, excretion, willingness, etc.)
8 children had difficulty sleeping for weeks 1 and 2.
6 children became more active for weeks 1 and 2.
Lee Dae Kun wrote that the parents, usually skeptical, saw the
improvements clearly. He concluded that DMG is very beneficial for
children with autism, even if it is not a cure.
Information about the use of DMG with older persons is also encouraging.
One mother of a 26-year-old who squeezed things (people, TV sets,
etc.) very hard when frustrated, tried DMG, quite skeptically, to
see if it would stimulate his very sparse speech. It didn't, but
brought remarkable improvement in his frustration tolerance. "Even
my husband, who was even more skeptical than me, now is a believer,"
she wrote.
DMG certainly doesn't always help, and it certainly is not a cure,
but it is certainly worth trying, in my humble opinion.
If you try it, let me hear from you.
This article appeared in the Autism Research Review
International, Vol. 4 (2), 1990, and updated in 1996. The Autism
Research Review International is a quarterly newsletter published
by the Autism Research Institute (4182 Adams Avenue, San Diego,
CA 92116, U.S.A.).
|